GiT Updates and More

Stepwise approach for the management of AIH-related decompensated cirrhosis

As Regard Hepatitis B

✳️ Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis. ▶️ Conclusion: Our results suggest that both agents are equally effective at controlling symptoms within two weeks of the first infusion, with a small number of patients receiving either having recurrent disease. The two drugs have a comparable safety profile with primarily mild AEs occurring. Our preliminary findings suggest that both drugs can be used effectively in first-line treatment of IMDC, but further data is necessary to ascertain long-term outcomes. Open Access

IBD and Cancers H.Q 👇

The Saline-Immersion/Irrigation TEchnique for Endoscopic Submucosal Dissection of Colorectal Lesions: Outcomes From a Large Western Cohort Open Access Conclusion ; Saline-Immersion/Irrigation Technique (SITE) + Pocket-Creation Method for colorectal ESD (n=181) showed: ✅ En bloc resection 🎯 R0 92.3% | Curative 90.6% ⏱️ Median time 120 min ⚠️ AEs only 4.4% ▶️ 93% done under conscious sedation

✳️ The dosage of diuretics for mild ascites should not be adjusted to alternate days or administered only two to three times per week, but rather should be given daily with careful titration and monitoring as per current guidelines. ▶️ Current guidelines recommend daily administration of diuretics (spironolactone, with or without furosemide) for the management of mild to moderate ascites, with dose titration based on clinical response, weight, and laboratory monitoring, and do not support alternate-day or less frequent dosing regimen. ▶️ Spironolactone's long half-life allows for once-daily dosing, but its pharmacodynamics require several days to reach steady state, and dose adjustments should be made cautiously every 72 hours, not by skipping days or reducing frequency to two or three times per week. ▶️ After ascites is controlled, diuretics should be tapered to the lowest effective daily dose to minimize adverse effects, but intermittent or non-daily dosing is not recommended in guidelines or expert reviews for maintenance, even in mild cases.

Low Albumin

Low Albumin

✳️ Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy ▶️ Conclusion: Rifaximin reduces the risk of readmissions for hepatic encephalopathy. One of the clearest cases where RCT-based effect sizes are reproducible in trials. Open Access

AASLD February 2026